CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
NAL ER +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05962151
NCT05962151Phase 2Completed
CompareCT.gov

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Period Crossover Efficacy and Safety Study of Nalbuphine ER Tablets for the Treatment of Refractory Chronic Cough

Trevi Therapeutics·interventional·Posted Jul 27, 2023·Updated Mar 30, 2026

In Brief

A Phase 2 clinical trial evaluating NAL ER and Placebo for Refractory Chronic Cough. Completed, enrolled 66 participants across 14 sites in 2 countries.

Detailed Summary

The main purpose of this study is to evaluate the effect of NAL ER on 24-hour cough frequency and to assess safety and tolerability of NAL-ER for treatment of refractory chronic cough.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Cough
CountriesCanada, United Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
202420252026
First PostedJul 27, 2023
Enrollment StartNov 30, 2023
Primary CompletionJan 6, 2025
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 2.9 years ago

Interventions

NAL ERdrug

Oral tablets

Placebodrug

Oral tablets